Cebon JS - Search Results

1

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Lau DK, Andrews MC, Turner N, Azad AA, Davis ID, Cebon JS. Lau DK, et al. Among authors: cebon js. Melanoma Res. 2014 Apr;24(2):144-9. doi: 10.1097/CMR.0000000000000036. Melanoma Res. 2014. PMID: 24463460

2

Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects.

Chen Q, Jackson H, Gibbs P, Davis ID, Trapani J, Cebon J. Chen Q, et al. Cancer Immunol Immunother. 1998 Dec;47(4):191-7. doi: 10.1007/s002620050520. Cancer Immunol Immunother. 1998. PMID: 9875671 Free PMC article.

3

A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.

Chen Q, Jackson H, Cebon J, Gibbs P, Davis ID, Trapani JA. Chen Q, et al. Melanoma Res. 2000 Feb;10(1):16-25. Melanoma Res. 2000. PMID: 10711636

4

A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.

Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME, Boyd AW. Davis ID, et al. Among authors: cebon js. Growth Factors. 2000;17(4):287-300. doi: 10.3109/08977190009028972. Growth Factors. 2000. PMID: 10801077 Clinical Trial.

5

MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS. Gibbs P, et al. Among authors: cebon js. Melanoma Res. 2000 Jun;10(3):259-64. Melanoma Res. 2000. PMID: 10890380

6

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, MacMillan J, Cohen B, Marty J, Fox RM, Begley CG. Basser RL, et al. J Clin Oncol. 2000 Aug;18(15):2852-61. doi: 10.1200/JCO.2000.18.15.2852. J Clin Oncol. 2000. PMID: 10920133 Clinical Trial.

7

Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation.

Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, Maraskovsky E, Cebon J. Luft T, et al. J Immunol. 2001 Sep 1;167(5):2529-37. doi: 10.4049/jimmunol.167.5.2529. J Immunol. 2001. PMID: 11509592

8

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ. Scott AM, et al. Among authors: cebon js. J Clin Oncol. 2001 Oct 1;19(19):3976-87. doi: 10.1200/JCO.2001.19.19.3976. J Clin Oncol. 2001. PMID: 11579119 Clinical Trial.

9

The use of dendritic cells in cancer therapy.

Jefford M, Maraskovsky E, Cebon J, Davis ID. Jefford M, et al. Lancet Oncol. 2001 Jun;2(6):343-53. doi: 10.1016/s1470-2045(00)00389-2. Lancet Oncol. 2001. PMID: 11905751 Review.

10

Rational approaches to human cancer immunotherapy.

Davis ID, Jefford M, Parente P, Cebon J. Davis ID, et al. J Leukoc Biol. 2003 Jan;73(1):3-29. doi: 10.1189/jlb.0502261. J Leukoc Biol. 2003. PMID: 12525559 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

251 results

Search Page